BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 16427303)

  • 1. Proteasome inhibitors in lung cancer.
    Scagliotti G
    Crit Rev Oncol Hematol; 2006 Jun; 58(3):177-89. PubMed ID: 16427303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential role of proteasome inhibitors in the treatment of lung cancer.
    Bunn PA
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4263s-4265s. PubMed ID: 15217971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteasome inhibition as a novel therapeutic target in human cancer.
    Rajkumar SV; Richardson PG; Hideshima T; Anderson KC
    J Clin Oncol; 2005 Jan; 23(3):630-9. PubMed ID: 15659509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
    Ludwig H; Khayat D; Giaccone G; Facon T
    Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Proteasome inhibitors: induction of apoptosis as new therapeutic option in prostate cancer].
    Tahmatzopoulos A; Gudegast C; Stöckle M; Wullich B; Unteregger G; Zwergel U; Zwergel T
    Aktuelle Urol; 2004 Nov; 35(6):491-6. PubMed ID: 15526229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Other compounds and targets in non-small cell lung cancer.
    Villaflor V; Bonomi P
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S30-6. PubMed ID: 16459177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib: a novel therapy approved for multiple myeloma.
    Richardson PG; Anderson KC
    Clin Adv Hematol Oncol; 2003 Oct; 1(10):596-600. PubMed ID: 16258456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of proteasome in malignant diseases.
    Moran E; Nencioni A
    J BUON; 2007 Sep; 12 Suppl 1():S95-9. PubMed ID: 17935285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
    Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
    Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The proteasome: a worthwhile target for the treatment of solid tumours?
    Milano A; Iaffaioli RV; Caponigro F
    Eur J Cancer; 2007 May; 43(7):1125-33. PubMed ID: 17379504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporating bortezomib into the treatment of lung cancer.
    Davies AM; Lara PN; Mack PC; Gandara DR
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4647-51. PubMed ID: 17671158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Proteasome inhibitors--new option in the treatment of tumor diseases].
    Spicka I; Klener P
    Cas Lek Cesk; 2004; 143(10):701-4. PubMed ID: 15584622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteasome inhibition as a therapeutic strategy for hematologic malignancies.
    Mitsiades CS; Mitsiades N; Hideshima T; Richardson PG; Anderson KC
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):465-76. PubMed ID: 16001954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The therapeutic potential of the proteasome in leukaemia.
    McCloskey SM; McMullin MF; Walker B; Irvine AE
    Hematol Oncol; 2008 Jun; 26(2):73-81. PubMed ID: 18324639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasome inhibition in multiple myeloma.
    Kropff M; Bisping G; Wenning D; Berdel WE; Kienast J
    Eur J Cancer; 2006 Jul; 42(11):1623-39. PubMed ID: 16820291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteasome inhibition: a new approach for the treatment of malignancies.
    Spano JP; Bay JO; Blay JY; Rixe O
    Bull Cancer; 2005 Nov; 92(11):E61-6, 945-52. PubMed ID: 16316823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteasome inhibition as novel treatment strategy in leukaemia.
    Vink J; Cloos J; Kaspers GJ
    Br J Haematol; 2006 Aug; 134(3):253-62. PubMed ID: 16787504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteasome inhibition for treatment of multiple myeloma: clinical update.
    Stadtmauer EA
    J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S10-5. PubMed ID: 19795531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The persisting challenge of selective and specific proteasome inhibition.
    Groll M; Huber R; Moroder L
    J Pept Sci; 2009 Feb; 15(2):58-66. PubMed ID: 19109822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular profiles of proteasome inhibition in plasma cell dyscrasias.
    Mitsiades CS
    J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S23-7. PubMed ID: 19795532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.